化合物Fanotaprim T36692

Product Introduction
Bioactivity


英文名: Fanotaprim

描述: Fanotaprim 是二氢叶酸还原酶的有效抑制剂，抑制 tgDHFR (Toxoplasma gondiiDHFR) 和 hDHFR (human DHFR)的 IC50分别为 1.57 和 308 nM。Fanotaprim 在研究弓形虫病方面具有价值。

体外活性: Fanotaprim had a parasiticidal EC50 of 13 nM against the type I RH strain of T. gondii. In human MCF-7 cells, Fanotaprim had an EC50 value of 7300 nM. The selectivity of Fanotaprim in the cell-based assays is in line with its DHFR selectivity profiles of 200-fold[1].

体内活性: Fanotaprim had moderate mouse liver microsome (MLM) intrinsic clearance (Clint) of 56.3 mL min–1 kg–1, which is 63% of mouse liver blood flow (LBF). Fanotaprim has low to moderate clearance of 10.6 mL min–1 kg–1, a volume of distribution of 1.14 L/kg, and a half-life of 3.9 h after a 1.0 mg/kg, iv dose. Oral bioavailability after a 0.83 mg/kg po dose was 47.3% with a Cmax of 178 ng/mL 30 min after dosing. The unbound fraction (%) in mouse plasma is 8.7 ± 0.2 and in brain homogenate 2.4 ± 0.3, determined using an equilibrium dialysis method. Fanotaprim was freely permeable into the mouse CNS at 0.5 h after a 10 mg/kg oral dose; the concentration in brain was 2560 ± 240 ng/g and in blood 1610 ± 580 ng/mL, giving a brain to blood ratio of 1.7 ± 0.6[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 25 mg/mL (66.06 mM)


关键字: CD-1 | Inhibitor | Fanotaprim | mice | VYR 006 | DHFR | VYR-006 | inhibit | Antifolate | dhydrofolate | reductase | survival | toxoplasmosis | VYR006

相关产品: Pyrimethamine | Piritrexim | Pelitrexol | 4′-DTMP | Pemetrexed disodium | Trimethoprim | LY 222306 | Diaveridine | 10-Formylfolic acid | DHFR-IN-4

相关库: Anti-Cancer Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Parasitic Compound Library | DNA Damage & Repair Compound Library | Metabolism Compound Library | Bioactive Compound Library

化合物Fanotaprim T36692信息由TargetMol中国为您提供，如您想了解更多关于化合物Fanotaprim T36692报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途